Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Organon and Co
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant has a diagnosis of essential hypertension.
Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication.
Participant has a mean trough SiDBP of \>=90mmHg and \< 110mmHg.
Participant has a mean trough SiSBP of \>=140mmHg and \< 200mmHg.
Participant has no clinically significant abnormality at screening visit.
You may not be if
Participant is currently taking \> 2 antihypertensive medications.
Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines).
Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.
Participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy test is positive at screening visit.
Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.
Clareo Health | A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
